Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tempest Therapeutics, Inc. - Common Stock (NQ:TPST)

9.380 +0.310 (+3.42%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tempest Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Reports Year End 2024 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Clinical data supporting mechanism of action reinforce potential as a novel cancer treatment 
From Tempest Therapeutics
Via GlobeNewswire
News headline image
FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
Second clinical program entering Phase 2 with data expected 2026 
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
The company is preparing for the Phase 3 study start in the first quarter of 2025 
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Extends Limited Duration Stockholder Rights Plan
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
Company welcomes additional late-stage expertise as it prepares for amezalpat pivotal study 
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
Expansion of leadership team to strengthen global clinical expertise 
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
Webcasted conference call on Thursday, June 20, 2024 at 8:30 a.m. ET 
From Tempest Therapeutics
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.